Davidson Zhao
Overview
Explore the profile of Davidson Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shi S, Zhou Q, Zhao D, Zarif M, Wei C, Sibai H, et al.
Leuk Res
. 2025 Feb;
151:107665.
PMID: 40020451
Background: Mixed-phenotype acute leukemia with BCR::ABL1 fusion (MPAL), previously known as Philadelphia chromosome-positive mixed phenotype acute leukemia, is a heterogeneous group that is segregated into different subtypes based on WHO-HAEM5....
2.
Zhao D, Rumina M, Zarif M, Wei C, Chang H
EJHaem
. 2024 Dec;
5(6):1370-1372.
PMID: 39691238
No abstract available.
3.
Zhou Q, Zhao D, Zarif M, Davidson M, Minden M, Tierens A, et al.
Blood Adv
. 2024 Jan;
8(7):1760-1771.
PMID: 38286462
The proposed fifth edition of the World Health Organization classification of hematolymphoid tumors (WHO-HAEM5) and International Consensus Classification (ICC) provide different definitions of acute myeloid leukemia with myelodysplasia-related genetics (AML-MR)....
4.
Zhao D, Zhou Q, Zarif M, Eladl E, Wei C, Atenafu E, et al.
Leuk Res
. 2023 Sep;
134:107376.
PMID: 37690321
AML with CEBPA mutation and AML with in-frame bZIP CEBPA mutations define favorable-risk disease entities in the proposed 5th edition of the World Health Organization Classification (WHO-HAEM5) and the International...
5.
Zhao D, Zarif M, Zhou Q, Capo-Chichi J, Schuh A, Minden M, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370821
mutations are associated with extremely poor outcomes in acute myeloid leukemia (AML). The outcomes of patients with -mutated () AML after different frontline treatment modalities are not well established. Allogeneic...
6.
Zhou Q, Zhao D, Zarif M, Yeung Y, Richard-Carpentier G, Chang H
Eur J Haematol
. 2023 May;
111(1):165-168.
PMID: 37165755
No abstract available.
7.
Zhou Q, Zhao D, Eladl E, Capo-Chichi J, Kim D, Chang H
Leuk Res
. 2022 Dec;
124:107002.
PMID: 36563650
Background: Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML) is a provisional disease entity in the 2016 WHO classification, while its genetic profile of Ph+ AML remains poorly defined. In addition,...
8.
Zhao D, Eladl E, Zarif M, Capo-Chichi J, Schuh A, Atenafu E, et al.
Cancer Med
. 2022 Nov;
12(6):6511-6522.
PMID: 36394085
Background: Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) generally confers poor prognosis, however, patient outcomes are heterogeneous. The impact of TP53 allelic state and variant allele frequency (VAF) in AML-MRC...
9.
Zhao D, Zarif M, Eladl E, Capo-Chichi J, Smith A, Atenafu E, et al.
Leuk Res
. 2022 May;
118:106869.
PMID: 35636054
Background: Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a prognostically diverse disease. Owing to its favourable prognosis, AML-MRC with mutated NPM1 (NPM1) diagnosed on the basis of multi-lineage dysplasia...
10.
Faruq O, Zhao D, Shrestha M, Vecchione A, Zacksenhaus E, Chang H
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326742
Background: MDM2 is elevated in multiple myeloma (MM). Although traditionally, MDM2 negatively regulates p53, a growing body of research suggests that MDM2 plays several p53-independent roles in cancer pathogenesis as...